Proactive London's Andrew Scott sat down with PLC's () chief medical officer Kathy Rickard.
Rickard recaps on the recent positive top-line Phase 2b results the firm reported for its COPD drug ensifentrine and discusses why she believes it has the potential to change patients' lives.
She says they're now looking forward to their planned meeting with the U.S. FDA which is due to take place in the second quarter.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE